United States Biotechnology & Medical Research

Aura Biosciences Inc (AURA)

Track

Aura Biosciences experienced notable insider selling activity recently, with executives offloading shares totaling over $82,000 in the last quarter. These transactions follow a period where the stock price remained relatively stable. No purchase activity was recorded, reflecting a trend of divestment among key leadership personnel following the company's latest earnings report.
Ticker: AURA Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Aura Biosciences Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Proposed sale 16 Jun 2026
Value US$4,721,921.45 | Price 400.45 | Shares 63,202
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-16 2026-06-16 PrS Proposed sale
2.8
Gibney Anthony

Officer

Officer
63,202
400.45
US$4,721,921 		63,202 400.45 US$4,721,921
2026-06-16 2026-06-16 S Sale
2.8
Gibney Anthony S

See Remarks

Officer
54,013 +48.2%
149.93
US$2,927,701 		54,013 +48.2% 149.93 US$2,927,701
2026-05-11 2026-05-07 S Sale
1.1
Matrix Capital Management Company, LP
Large shareholder
73,353 +33.7%
262.69
US$4,767,711 		73,353 +33.7% 262.69 US$4,767,711
2026-04-16 2026-04-16 PrS Proposed sale
1.4
Kilroy Conor

Officer

Officer
11,738
7.02
US$82,402 		11,738 7.02 US$82,402
2026-04-16 2026-04-16 S Sale
1.4
Kilroy Conor

See Remarks

Officer
11,738 -5.1%
7.02
US$82,401 		11,738 -5.1% 7.02 US$82,401
2026-02-17 2026-02-17 PrS Proposed sale
1.4
Kilroy Conor

Officer

Officer
12,079
5.05
US$61,037 		12,079 5.05 US$61,037
2026-02-17 2026-02-17 PrS Proposed sale
2.8
Elazzouzi Amy

Officer

Officer
8,549
5.06
US$43,261 		8,549 5.06 US$43,261
2026-02-17 2026-02-17 PrS Proposed sale
2.4
Hopkins Janet Jill

Officer

Officer
20,401
5.06
US$103,231 		20,401 5.06 US$103,231
2026-02-17 2026-02-17 PrS Proposed sale
2.8
de los Pinos Elisabet

Officer; Director

Executive Director
47,648
5.06
US$241,063 		47,648 5.06 US$241,063
2026-02-17 2026-02-17 PrS Proposed sale
3.0
Plavsic Mark

Officer

Officer
15,890
5.05
US$80,271 		15,890 5.05 US$80,271
2026-02-17 2026-02-17 S Sale
2.4
Hopkins Janet Jill

Chief Medical Officer

Officer
20,401 -8.1%
5.06
US$103,229 		20,401 -8.1% 5.06 US$103,229
2026-02-17 2026-02-17 S Sale
1.4
Kilroy Conor

See Remarks

Officer
12,079 -6.7%
5.05
US$60,999 		12,079 -6.7% 5.05 US$60,999
2026-02-17 2026-02-17 S Sale
3.0
Plavsic Mark

Chief Technology Officer

Officer
15,890 -8.1%
5.05
US$80,244 		15,890 -8.1% 5.05 US$80,244
2026-02-17 2026-02-17 S Sale
2.8
de los Pinos Elisabet

See Remarks

Executive Director
47,648 -10.4%
5.06
US$241,099 		47,648 -10.4% 5.06 US$241,099
2026-02-17 2026-02-17 S Sale
2.8
Elazzouzi Amy

Senior Vice President, Finance

Officer
8,549 -10.2%
5.06
US$43,258 		8,549 -10.2% 5.06 US$43,258
2026-01-20 2026-01-20 PrS Proposed sale
2.8
Elazzouzi Amy

Officer

Officer
1,581
4.86
US$7,684 		1,581 4.86 US$7,684
2026-01-20 2026-01-20 PrS Proposed sale
2.8
de los Pinos Elisabet

Officer; Director

Executive Director
16,928
4.86
US$82,234 		16,928 4.86 US$82,234
2026-01-20 2026-01-20 S Sale
2.8
Elazzouzi Amy

Senior Vice President, Finance

Officer
1,581 -1.8%
4.86
US$7,684 		1,581 -1.8% 4.86 US$7,684
2026-01-20 2026-01-20 S Sale
2.8
de los Pinos Elisabet

See Remarks

Executive Director
16,928 -3.6%
4.86
US$82,270 		16,928 -3.6% 4.86 US$82,270
2025-11-17 2025-11-17 PrS Proposed sale
2.4
Hopkins Janet Jill

Officer

Officer
17,109
5.42
US$92,735 		17,109 5.42 US$92,735
2025-11-17 2025-11-17 S Sale
2.4
Hopkins Janet Jill

Chief Medical Officer

Officer
17,109 -6.3%
5.42
US$92,731 		17,109 -6.3% 5.42 US$92,731
2025-10-29 2025-10-29 PrS Proposed sale
2.8
Elazzouzi Amy

Officer

Officer
896
6.35
US$5,690 		896 6.35 US$5,690
2025-10-29 2025-10-29 PrS Proposed sale
2.8
de los Pinos Elisabet

Officer; Director

Executive Director
9,049
6.35
US$57,461 		9,049 6.35 US$57,461
2025-10-29 2025-10-29 S Sale
2.8
Elazzouzi Amy

Senior Vice President, Finance

Officer
896 -1.0%
6.35
US$5,690 		896 -1.0% 6.35 US$5,690
2025-10-29 2025-10-29 S Sale
2.8
de los Pinos Elisabet

See Remarks

Executive Director
9,049 -1.9%
6.35
US$57,461 		9,049 -1.9% 6.35 US$57,461
2025-10-16 2025-10-16 PrS Proposed sale
3.0
Plavsic Mark

Officer

Officer
12,169
6.35
US$77,273 		12,169 6.35 US$77,273
2025-10-16 2025-10-16 S Sale
3.0
Plavsic Mark

Chief Technology Officer

Officer
12,169 -5.8%
6.35
US$77,273 		12,169 -5.8% 6.35 US$77,273
2025-08-18 2025-08-18 PrS Proposed sale
2.8
AMY F ELAZZOUZI

Officer

Officer
7,722
6.70
US$51,751 		7,722 6.70 US$51,751
2025-08-18 2025-08-18 S Sale
2.8
Elazzouzi Amy

Senior Vice President, Finance

Officer
7,722 -8.2%
6.70
US$51,737 		7,722 -8.2% 6.70 US$51,737
2025-05-20 2025-05-16 B Purchase
3.8
Johnson David Michael
Non-Executive Director
20,000 +13.7%
4.90
US$98,000 		20,000 +13.7% 4.90 US$98,000
2025-05-20 2025-05-16 S Sale
2.8
Gibney Anthony S

See Remarks

Officer
1,519 -2.6%
5.15
US$7,823 		1,519 -2.6% 5.15 US$7,823
2025-05-20 2025-05-16 B Purchase
2.8
Gibney Anthony S

See Remarks

Officer
50,000 +591.6%
4.90
US$245,000 		50,000 +591.6% 4.90 US$245,000
2025-05-16 2025-05-16 PrS Proposed sale
2.8
Gibney Anthony

Officer

Officer
1,519
5.15
US$7,823 		1,519 5.15 US$7,823
2025-04-16 2025-04-16 PrS Proposed sale
2.8
Elazzouzi Amy

Officer

Officer
897
5.49
US$4,925 		897 5.49 US$4,925
2025-04-16 2025-04-16 PrS Proposed sale
1.4
Kilroy Conor

Officer

Officer
7,162
5.49
US$39,319 		7,162 5.49 US$39,319
2025-04-16 2025-04-16 S Sale
2.8
Elazzouzi Amy

Senior Vice President, Finance

Officer
897 -1.1%
5.49
US$4,925 		897 -1.1% 5.49 US$4,925
2025-04-16 2025-04-16 S Sale
1.4
Kilroy Conor

See Remarks

Officer
7,162 -3.8%
5.49
US$39,319 		7,162 -3.8% 5.49 US$39,319
2025-02-18 2025-02-18 PrS Proposed sale
3.0
Plavsic Mark

Officer

Officer
2,151
7.75
US$16,670 		2,151 7.75 US$16,670
2025-02-18 2025-02-18 PrS Proposed sale
2.4
Hopkins Janet Jill

Officer

Officer
2,534
7.75
US$19,639 		2,534 7.75 US$19,639
2025-02-18 2025-02-18 PrS Proposed sale
2.8
Elazzouzi Amy

Officer

Officer
1,404
7.75
US$10,881 		1,404 7.75 US$10,881
2025-02-18 2025-02-18 PrS Proposed sale
2.8
de los Pinos Elisabet

Officer; Director

Executive Director
20,221
7.75
US$156,796 		20,221 7.75 US$156,796
2025-02-18 2025-02-18 S Sale
3.0
Plavsic Mark

Chief Technology Officer

Officer
2,151 -1.0%
7.75
US$16,670 		2,151 -1.0% 7.75 US$16,670
2025-02-18 2025-02-18 S Sale
2.4
Hopkins Janet Jill

Chief Medical Officer

Officer
2,534 -0.9%
7.75
US$19,638 		2,534 -0.9% 7.75 US$19,638
2025-02-18 2025-02-18 S Sale
2.8
de los Pinos Elisabet

See Remarks

Executive Director
20,221 -4.0%
7.75
US$156,796 		20,221 -4.0% 7.75 US$156,796
2025-02-18 2025-02-18 S Sale
2.8
Elazzouzi Amy

Senior Vice President, Finance

Officer
1,404 -1.7%
7.75
US$10,881 		1,404 -1.7% 7.75 US$10,881
2025-01-21 2025-01-21 PrS Proposed sale
2.8
de los Pinos Elisabet

Officer; Director

Executive Director
15,955
7.67
US$122,381 		15,955 7.67 US$122,381
2025-01-21 2025-01-21 PrS Proposed sale
2.8
Elazzouzi Amy

Officer

Officer
1,001
7.67
US$7,679 		1,001 7.67 US$7,679
2025-01-21 2025-01-21 S Sale
2.8
de los Pinos Elisabet

See Remarks

Executive Director
15,955 -5.0%
7.67
US$122,381 		15,955 -5.0% 7.67 US$122,381
2025-01-21 2025-01-21 S Sale
2.8
Elazzouzi Amy

Vice President, Finance

Officer
1,001 -2.5%
7.67
US$7,679 		1,001 -2.5% 7.67 US$7,679
2024-11-18 2024-11-18 PrS Proposed sale
2.4
Janet Jill Hopkins

Officer

Officer
11,822
9.36
US$110,663 		11,822 9.36 US$110,663
2024-11-18 2024-11-18 S Sale
2.4
Hopkins Janet Jill

Chief Medical Officer

Officer
11,822 -7.2%
9.36
US$110,663 		11,822 -7.2% 9.36 US$110,663
2024-10-29 2024-10-29 PrS Proposed sale
2.8
Amy Elazzouzi

Officer

Officer
553
10.74
US$5,938 		553 10.74 US$5,938
2024-10-29 2024-10-29 PrS Proposed sale
2.8
Elisabet de los Pinos

Officer; Director

Executive Director
9,200
10.74
US$98,788 		9,200 10.74 US$98,788
2024-10-29 2024-10-29 PrS Proposed sale
1.9
Julie B. Feder

Former Officer

Officer
3,249
10.74
US$34,889 		3,249 10.74 US$34,889
2024-10-29 2024-10-29 S Sale
2.8
de los Pinos Elisabet

See Remarks

Executive Director
9,200 -2.8%
10.74
US$98,788 		9,200 -2.8% 10.74 US$98,788
2024-10-29 2024-10-29 S Sale
2.8
Elazzouzi Amy

Vice President, Finance

Officer
553 -1.4%
10.74
US$5,938 		553 -1.4% 10.74 US$5,938
2024-10-21 2024-10-18 PlS Planned sale
1.9
Feder Julie B

Chief Financial Officer

Officer
25,131 -15.8%
12.03
US$302,361 		25,131 -15.8% 12.03 US$302,361
2024-10-18 2024-10-18 PrS Proposed sale
1.9
JULIE FEDER

Officer

Officer
25,131
10.29
US$258,598 		25,131 10.29 US$258,598
2024-10-18 2024-10-18 PrS Proposed sale
2.8
ELISABET DE LOS PINOS

Director; Officer

Executive Director
24,992
10.29
US$257,168 		24,992 10.29 US$257,168
2024-10-18 2024-10-18 PlS Planned sale
2.8
de los Pinos Elisabet

See Remarks

Executive Director
24,992 -7.0%
12.04
US$300,839 		24,992 -7.0% 12.04 US$300,839
2024-10-16 2024-10-16 PrS Proposed sale
3.0
Plavsic Mark

Officer

Officer
7,383
9.85
US$72,723 		7,383 9.85 US$72,723
2024-10-16 2024-10-16 S Sale
3.0
Plavsic Mark

Chief Technology Officer

Officer
7,383 -5.7%
9.85
US$72,723 		7,383 -5.7% 9.85 US$72,723
2024-03-04 2024-03-04 PrS Proposed sale
CADMUS C RICH & SHANTEL C RICH

Officer

Officer
20,000
9.24
US$184,800 		20,000 9.24 US$184,800
2024-02-23 2024-02-23 PrS Proposed sale
CADMUS C RICH & SHANTEL C RICH

Officer

Officer
15,974
8.73
US$139,453 		15,974 8.73 US$139,453
2024-01-24 2024-01-23 PrS Proposed sale
1.9
Julie B. Feder

Officer

Officer
6,609
7.64
US$50,521 		6,609 7.64 US$50,521
2024-01-24 2024-01-23 PrS Proposed sale
2.8
Elisabet de los Pinos

Officer; Director

Executive Director
15,853
7.64
US$121,141 		15,853 7.64 US$121,141
2024-01-24 2024-01-23 S Sale
1.9
Feder Julie B

Chief Financial Officer

Officer
6,609 -9.5%
7.64
US$50,521 		6,609 -9.5% 7.64 US$50,521
2024-01-24 2024-01-23 S Sale
2.8
de los Pinos Elisabet

See Remarks

Executive Director
15,853 -8.9%
7.64
US$121,141 		15,853 -8.9% 7.64 US$121,141
2024-01-08 2024-01-08 PrS Proposed sale
CADMUS C RICH & SHANTEL C RICH JT TEN

Officer

Officer
10,000
8.85
US$88,500 		10,000 8.85 US$88,500
2024-01-02 2024-01-02 PrS Proposed sale
CADMUS C RICH & SHANTEL C RICH JT TEN

Officer

Officer
9,748
8.86
US$86,367 		9,748 8.86 US$86,367
2023-12-15 2023-12-15 PrS Proposed sale
CADMUS C RICH &SHANTEL C RICH JT TEN

Officer

Officer
90,039
8.85
US$796,845 		90,039 8.85 US$796,845
2023-11-09 2023-11-09 B Purchase
1.1
Matrix Capital Management Company, LP
Large shareholder
1,560,000 +29.1%
9.00
US$14,040,000 		1,560,000 +29.1% 9.00 US$14,040,000
2023-11-09 2023-11-08 B Purchase
3.8
Johnson David Michael
Non-Executive Director
10,000 +15.4%
7.30
US$73,000 		10,000 +15.4% 7.30 US$73,000
2023-11-09 2023-11-08 B Purchase
3.8
Johnson David Michael
Non-Executive Director
10,000 +15.4%
7.30
US$73,000 		10,000 +15.4% 7.30 US$73,000
2023-11-09 2023-11-08 B Purchase
3.8
Johnson David Michael
Non-Executive Director
9,601 +7.6%
7.30
US$70,087 		9,601 +7.6% 7.30 US$70,087
Explore more

More insider trading research around Aura Biosciences Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America